Treatment of intracranial aneurysms using the new Surpass Evolve flow diverter: Safety outcomes and six-month imaging follow-up

Rautio, Riitta; Alpay, Kemal; Sinisalo, Matias; Numminen, Jussi

doi:10.1016/j.neurad.2021.03.003

Cited by 12 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the Food and Drug Administration (FDA), in 2011, authorized the use of the first Flow diverter (Pipeline Embolization Device, Medtronic, Dublin, Ireland), flow diverters (FDs) began to be used representing an important option in the treatment of large and long brain aneurysms, obtaining satisfactory results both in the degree of occlusion and in the clinical efficacy (1)(2)(3)(4)(5)(6)(7)(8). The neurovascular community has been progressively increasing their use, developing a new-generation the FDs, with different structures, in order to produce better parent artery reconstruction and improve endothelial cells formation across the aneurysm neck (Silk flow diverter, Balt Extrusion, Montmorency, France; FRED, MicroVention, Tustin, CA; Derivo Embolization Device, Acandis GmbH, Germany; Surpass stent, Stryker Neurovascular, Kalamazoo, MI, USA; p64, Phenox GmbH, Bochum, Germany) (9)(10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Treatment of Intracranial Aneurysms Using the New Silk Vista Flow Diverter: Safety Outcomes at Short-Term Follow-Up

Pumar

Mosqueira

Olier³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Background: Flow diverters are widely used as the first endovascular treatment option for complex brain aneurysms due to their high percentage of occlusion and low morbi-mortality. The Silk Vista device is a new generation of flow diverters designed to facilitate full visibility, improve apposition to the vessel wall, and enhance navigability. Indeed, its greatest advantage is that it enables the easier navigation of stents between 3.5 and 4.75 mm through a 0.021 microcatheter. The objective of this study was to evaluate the safety and effectiveness of Silk Vista systems for treating cerebral aneurysms.Methods: This prospective observational study included 25 consecutive patients with 27 wide-necked unruptured aneurysms treated with SILK Vista who were retrospectively analyzed for safety and efficacy.Results: Endovascular treatment was successfully performed in all patients. The final morbidity and mortality rates were both 0.0%. Short-term (3–5 months) angiographic follow-up revealed 21 complete occlusions and 6 near-complete occlusions. No significant parent artery stenosis was observed.Conclusions: This report demonstrates the efficacy of Silk Vista in treating brain aneurysms, although longer experiences should be carried out to confirm our results.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of Intracranial Aneurysms Using the New Silk Vista Flow Diverter: Safety Outcomes at Short-Term Follow-Up

Pumar

Mosqueira

Olier³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Subsequently, 904 documents were excluded based on title and abstract screening against the inclusion/exclusion criteria. A further 38 were excluded at the full-text screening for not meeting the inclusion criteria, leaving five studies for quality assessment [ 15 , 16 , 21 , 22 , 23 ] (see Figure 1 for PRISMA flow chart).…”

Section: Resultsmentioning

confidence: 99%

“…However, due to the very limited number of available studies, none were excluded at the quality assessment stage. A total of three case series scored 5/5 stars [ 15 , 22 , 23 ]. The remaining case series [ 16 ] scored 4/5 stars.…”

Section: Resultsmentioning

confidence: 99%

“…A total of three studies used the retrospective case series design [ 15 , 22 , 23 ], one used the prospective case series [ 16 ], and one used the retrospective cohort design [ 21 ]. Two studies were conducted in the Republic of Korea [ 21 , 22 ], two in Europe [ 15 , 23 ], and one in Canada [ 16 ]. The mean age for the participants ranged between 54.6 and 58 years.…”

Section: Resultsmentioning

confidence: 99%

“…This change caused a challenge in the navigation and deployment of the FDS [ 5 ]. Thus, Surpass Evolve-Flow Diverter (SE-FD) was introduced in 2019 as an updated version of the previous surpass model [ 15 ]. To optimize and maintain the flow diversion effect and maintain effective navigation and deployment, SE-FD uses 64 wires [ 6 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Surpass Evolve Flow Diverter for the Treatment of Intracranial Aneurysm: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Purpose: This systematic review aims to summarize the evidence investigating the effectiveness and safety of the Surpass Evolve-Flow Diverter (SE-FD) to treat brain aneurysms. Method: We searched MEDLINE, EMBASE, CINAHL, Web of Science, and Cochrane Library from January 2019 to 29 March 2022. Terms related to the “intracranial aneurysm” and “surpass evolve flow diverter” concepts were used to search the databases; Medical Subject Headings (MeSH) and reference hand search were also utilized. Results: The searches primarily identified 1586 documents. A total of five studies (four case series and one cohort) were included in this review. In the included studies, 192 (74 male and 118 females) patients with 198 aneurysms were involved. In total, 153 SE-FDs were used to treat 145 aneurysms. Complete occlusion was achieved in 69/145 (48%) cases and near-complete occlusion in 24/145 (17%) cases from aneurysms treated with SE-FD. Reported postoperative complications included stent thrombosis (n = 4 patients), hemorrhage (n = 5 patients), ischemia (n = 9 patients), and neurological complications (n = 12 patients). In total, four deaths were reported with only one related to the SE-FD procedure. Conclusion: The results of this review are based on observational data, due to the absence of clinical trials. The findings of the included studies suggest that the effectiveness of the SE-FD procedure is lower than previous FDs but the safety is similar. The included studies also suggested that SE-FD has navigability and resistance to twisting, which makes the procedure an easier method to treat aneurysms that are proximal and distal to the circle of Willis deployment. This review highlights the urgency to conduct clinical trials to confirm these suggestions.

show abstract

Ultra-Early “Fishmouth stenosis” and thrombosis of a Surpass Evolve flow diversion device following treatment of multiples right siphon aneurysms

Torche,

Cao,

Mattar

et al. 2023

Neuroradiology

View full text Add to dashboard Cite

Treatment of intracranial aneurysms using the new Surpass Evolve flow diverter: Safety outcomes and six-month imaging follow-up

Cited by 12 publications

References 23 publications

Treatment of Intracranial Aneurysms Using the New Silk Vista Flow Diverter: Safety Outcomes at Short-Term Follow-Up

Treatment of Intracranial Aneurysms Using the New Silk Vista Flow Diverter: Safety Outcomes at Short-Term Follow-Up

Surpass Evolve Flow Diverter for the Treatment of Intracranial Aneurysm: A Systematic Review

Ultra-Early “Fishmouth stenosis” and thrombosis of a Surpass Evolve flow diversion device following treatment of multiples right siphon aneurysms

Contact Info

Product

Resources

About